Present status of the zinc glycinate marker (ZGM)

ZGM was purified from both primary and metastatic colonic carcinomas demonstrably positive for ZGM by immunofluorescence microscopy. ZGM purification included preparative Pevikon electrophoresis, Sepharose 4B molecular exclusion chromatography and Con A‐Sepharose affinity chromatography. ZGM had an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1978-09, Vol.42 (S3), p.1621-1625
Hauptverfasser: Saravis, C. A., Oh, S. K., Pusztaszeri, G., Doos, W., Zamcheck, N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1625
container_issue S3
container_start_page 1621
container_title Cancer
container_volume 42
creator Saravis, C. A.
Oh, S. K.
Pusztaszeri, G.
Doos, W.
Zamcheck, N.
description ZGM was purified from both primary and metastatic colonic carcinomas demonstrably positive for ZGM by immunofluorescence microscopy. ZGM purification included preparative Pevikon electrophoresis, Sepharose 4B molecular exclusion chromatography and Con A‐Sepharose affinity chromatography. ZGM had an α2 electrophoretic mobility, an estimated molecular weight by Sepharose 4B equal to or greater than 2 × 106, and did not bind to Con A‐Sepharose, although having determinants with CEA‐like activity. Its immunologic activity was resistant to trypsin or phospholipase A but not to neuraminidase. Antisera prepared to ZGM and absorbed with saliva, when tested by double immunodiffusion, formed a single precipitation line with saline extracts of colon tumors and did not cross‐react with CEA, AFP, normal tissue extracts, ferritin, NCA, NCA‐2, CSAp, blood groups A, B, H, Lewis antigen, or buffy coat, alpha‐2 macroblogulin, saliva or ovarian cyst fluid. Immunofluorescence microscopy confirmed the presence of ZGM in 40 out of 45 adenocarcinomas of the GI tract staining primarily in tumors, the apical cytoplasm, and in grossly nonmalignant tissues, the deep crypts of the villi, while all of 22 non‐GI tumors in the study were ZGM negative.
doi_str_mv 10.1002/1097-0142(197809)42:3+<1621::AID-CNCR2820420841>3.0.CO;2-C
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_74241488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>74241488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4631-b506975336998ad3f6f6ce497a7a2bc2dbd859a54e09ac2043d84c0deec7a2913</originalsourceid><addsrcrecordid>eNqNkNtLwzAUxoN4m5f_wIc-iUM6Ty5tkynCrFdQJ6IgvhyyNNVqt2nTIfOvN7Mi6IP4lITvy_ed8yPkgEKHArAdCioJgQq2RVUiQbUF6_LtPRoz2u32zg7D9DK9ZpKBYCAF3ecd6KT9XRamc6T1_XmetABAhpHgd8tkxbkn_0xYxJfIYgIqYrJF6FVlnR3Vgat1PXHBOA_qRxu8FyMTPJRTU4x0bYOhrp5tFWzdn1y018hCrktn17_OVXJ7fHSTnobn_ZOztHceGhFzGg4iiFUScR4rJXXG8ziPjRUq0YlmA8OyQSYjpSNhQWnjN-GZFAYya403KMpXyWaT-1KNXyfW1TgsnLFlqUd2PHGYCCaokNIb7xujqcbOVTbHl6rwE0-RAs5w4owIzohggxP9jSPOcCJ6nPgTp9cA0z4yTH34xtcUk8HQZt_RDT8vZ438VpR2-s_iz94_a38p_AOJ2o_v</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>74241488</pqid></control><display><type>article</type><title>Present status of the zinc glycinate marker (ZGM)</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Saravis, C. A. ; Oh, S. K. ; Pusztaszeri, G. ; Doos, W. ; Zamcheck, N.</creator><creatorcontrib>Saravis, C. A. ; Oh, S. K. ; Pusztaszeri, G. ; Doos, W. ; Zamcheck, N.</creatorcontrib><description>ZGM was purified from both primary and metastatic colonic carcinomas demonstrably positive for ZGM by immunofluorescence microscopy. ZGM purification included preparative Pevikon electrophoresis, Sepharose 4B molecular exclusion chromatography and Con A‐Sepharose affinity chromatography. ZGM had an α2 electrophoretic mobility, an estimated molecular weight by Sepharose 4B equal to or greater than 2 × 106, and did not bind to Con A‐Sepharose, although having determinants with CEA‐like activity. Its immunologic activity was resistant to trypsin or phospholipase A but not to neuraminidase. Antisera prepared to ZGM and absorbed with saliva, when tested by double immunodiffusion, formed a single precipitation line with saline extracts of colon tumors and did not cross‐react with CEA, AFP, normal tissue extracts, ferritin, NCA, NCA‐2, CSAp, blood groups A, B, H, Lewis antigen, or buffy coat, alpha‐2 macroblogulin, saliva or ovarian cyst fluid. Immunofluorescence microscopy confirmed the presence of ZGM in 40 out of 45 adenocarcinomas of the GI tract staining primarily in tumors, the apical cytoplasm, and in grossly nonmalignant tissues, the deep crypts of the villi, while all of 22 non‐GI tumors in the study were ZGM negative.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(197809)42:3+&lt;1621::AID-CNCR2820420841&gt;3.0.CO;2-C</identifier><identifier>PMID: 709528</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antigens, Neoplasm ; Chromatography, Gel ; Colonic Neoplasms - metabolism ; Glycine - analogs &amp; derivatives ; Glycine - metabolism ; Humans ; Neoplasm Metastasis ; Neoplasm Proteins - metabolism ; Zinc - immunology ; Zinc - metabolism</subject><ispartof>Cancer, 1978-09, Vol.42 (S3), p.1621-1625</ispartof><rights>Copyright © 1978 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4631-b506975336998ad3f6f6ce497a7a2bc2dbd859a54e09ac2043d84c0deec7a2913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/709528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saravis, C. A.</creatorcontrib><creatorcontrib>Oh, S. K.</creatorcontrib><creatorcontrib>Pusztaszeri, G.</creatorcontrib><creatorcontrib>Doos, W.</creatorcontrib><creatorcontrib>Zamcheck, N.</creatorcontrib><title>Present status of the zinc glycinate marker (ZGM)</title><title>Cancer</title><addtitle>Cancer</addtitle><description>ZGM was purified from both primary and metastatic colonic carcinomas demonstrably positive for ZGM by immunofluorescence microscopy. ZGM purification included preparative Pevikon electrophoresis, Sepharose 4B molecular exclusion chromatography and Con A‐Sepharose affinity chromatography. ZGM had an α2 electrophoretic mobility, an estimated molecular weight by Sepharose 4B equal to or greater than 2 × 106, and did not bind to Con A‐Sepharose, although having determinants with CEA‐like activity. Its immunologic activity was resistant to trypsin or phospholipase A but not to neuraminidase. Antisera prepared to ZGM and absorbed with saliva, when tested by double immunodiffusion, formed a single precipitation line with saline extracts of colon tumors and did not cross‐react with CEA, AFP, normal tissue extracts, ferritin, NCA, NCA‐2, CSAp, blood groups A, B, H, Lewis antigen, or buffy coat, alpha‐2 macroblogulin, saliva or ovarian cyst fluid. Immunofluorescence microscopy confirmed the presence of ZGM in 40 out of 45 adenocarcinomas of the GI tract staining primarily in tumors, the apical cytoplasm, and in grossly nonmalignant tissues, the deep crypts of the villi, while all of 22 non‐GI tumors in the study were ZGM negative.</description><subject>Antigens, Neoplasm</subject><subject>Chromatography, Gel</subject><subject>Colonic Neoplasms - metabolism</subject><subject>Glycine - analogs &amp; derivatives</subject><subject>Glycine - metabolism</subject><subject>Humans</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Zinc - immunology</subject><subject>Zinc - metabolism</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1978</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkNtLwzAUxoN4m5f_wIc-iUM6Ty5tkynCrFdQJ6IgvhyyNNVqt2nTIfOvN7Mi6IP4lITvy_ed8yPkgEKHArAdCioJgQq2RVUiQbUF6_LtPRoz2u32zg7D9DK9ZpKBYCAF3ecd6KT9XRamc6T1_XmetABAhpHgd8tkxbkn_0xYxJfIYgIqYrJF6FVlnR3Vgat1PXHBOA_qRxu8FyMTPJRTU4x0bYOhrp5tFWzdn1y018hCrktn17_OVXJ7fHSTnobn_ZOztHceGhFzGg4iiFUScR4rJXXG8ziPjRUq0YlmA8OyQSYjpSNhQWnjN-GZFAYya403KMpXyWaT-1KNXyfW1TgsnLFlqUd2PHGYCCaokNIb7xujqcbOVTbHl6rwE0-RAs5w4owIzohggxP9jSPOcCJ6nPgTp9cA0z4yTH34xtcUk8HQZt_RDT8vZ438VpR2-s_iz94_a38p_AOJ2o_v</recordid><startdate>197809</startdate><enddate>197809</enddate><creator>Saravis, C. A.</creator><creator>Oh, S. K.</creator><creator>Pusztaszeri, G.</creator><creator>Doos, W.</creator><creator>Zamcheck, N.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197809</creationdate><title>Present status of the zinc glycinate marker (ZGM)</title><author>Saravis, C. A. ; Oh, S. K. ; Pusztaszeri, G. ; Doos, W. ; Zamcheck, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4631-b506975336998ad3f6f6ce497a7a2bc2dbd859a54e09ac2043d84c0deec7a2913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1978</creationdate><topic>Antigens, Neoplasm</topic><topic>Chromatography, Gel</topic><topic>Colonic Neoplasms - metabolism</topic><topic>Glycine - analogs &amp; derivatives</topic><topic>Glycine - metabolism</topic><topic>Humans</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Zinc - immunology</topic><topic>Zinc - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saravis, C. A.</creatorcontrib><creatorcontrib>Oh, S. K.</creatorcontrib><creatorcontrib>Pusztaszeri, G.</creatorcontrib><creatorcontrib>Doos, W.</creatorcontrib><creatorcontrib>Zamcheck, N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saravis, C. A.</au><au>Oh, S. K.</au><au>Pusztaszeri, G.</au><au>Doos, W.</au><au>Zamcheck, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Present status of the zinc glycinate marker (ZGM)</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1978-09</date><risdate>1978</risdate><volume>42</volume><issue>S3</issue><spage>1621</spage><epage>1625</epage><pages>1621-1625</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>ZGM was purified from both primary and metastatic colonic carcinomas demonstrably positive for ZGM by immunofluorescence microscopy. ZGM purification included preparative Pevikon electrophoresis, Sepharose 4B molecular exclusion chromatography and Con A‐Sepharose affinity chromatography. ZGM had an α2 electrophoretic mobility, an estimated molecular weight by Sepharose 4B equal to or greater than 2 × 106, and did not bind to Con A‐Sepharose, although having determinants with CEA‐like activity. Its immunologic activity was resistant to trypsin or phospholipase A but not to neuraminidase. Antisera prepared to ZGM and absorbed with saliva, when tested by double immunodiffusion, formed a single precipitation line with saline extracts of colon tumors and did not cross‐react with CEA, AFP, normal tissue extracts, ferritin, NCA, NCA‐2, CSAp, blood groups A, B, H, Lewis antigen, or buffy coat, alpha‐2 macroblogulin, saliva or ovarian cyst fluid. Immunofluorescence microscopy confirmed the presence of ZGM in 40 out of 45 adenocarcinomas of the GI tract staining primarily in tumors, the apical cytoplasm, and in grossly nonmalignant tissues, the deep crypts of the villi, while all of 22 non‐GI tumors in the study were ZGM negative.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>709528</pmid><doi>10.1002/1097-0142(197809)42:3+&lt;1621::AID-CNCR2820420841&gt;3.0.CO;2-C</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1978-09, Vol.42 (S3), p.1621-1625
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_74241488
source MEDLINE; Alma/SFX Local Collection
subjects Antigens, Neoplasm
Chromatography, Gel
Colonic Neoplasms - metabolism
Glycine - analogs & derivatives
Glycine - metabolism
Humans
Neoplasm Metastasis
Neoplasm Proteins - metabolism
Zinc - immunology
Zinc - metabolism
title Present status of the zinc glycinate marker (ZGM)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A31%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Present%20status%20of%20the%20zinc%20glycinate%20marker%20(ZGM)&rft.jtitle=Cancer&rft.au=Saravis,%20C.%20A.&rft.date=1978-09&rft.volume=42&rft.issue=S3&rft.spage=1621&rft.epage=1625&rft.pages=1621-1625&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/1097-0142(197809)42:3+%3C1621::AID-CNCR2820420841%3E3.0.CO;2-C&rft_dat=%3Cproquest_cross%3E74241488%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=74241488&rft_id=info:pmid/709528&rfr_iscdi=true